ValuEngine upgraded shares of Capricor Therapeutics Inc (OTCMKTS:CAPR) from a strong sell rating to a sell rating in a research report report published on Monday morning.

CAPR has been the topic of several other research reports. Rodman & Renshaw restated a buy rating and issued a $2.15 price target on shares of Capricor Therapeutics in a research report on Saturday, July 22nd. Zacks Investment Research upgraded Capricor Therapeutics from a hold rating to a buy rating and set a $1.25 price target on the stock in a research report on Wednesday, August 16th. Finally, HC Wainwright set a $2.00 price target on Capricor Therapeutics and gave the company a buy rating in a research report on Tuesday, July 18th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Capricor Therapeutics has an average rating of Buy and an average target price of $5.48.

Shares of Capricor Therapeutics (CAPR) opened at 2.81 on Monday. The stock’s market cap is $66.02 million. The stock has a 50 day moving average price of $1.60 and a 200-day moving average price of $1.68. Capricor Therapeutics has a 52 week low of $0.63 and a 52 week high of $4.25.

Capricor Therapeutics (OTCMKTS:CAPR) last issued its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.02. The company had revenue of $1.00 million during the quarter, compared to analyst estimates of $1.10 million. Equities analysts predict that Capricor Therapeutics will post ($0.70) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at

A hedge fund recently raised its stake in Capricor Therapeutics stock. Virtu KCG Holdings LLC raised its holdings in Capricor Therapeutics Inc (OTCMKTS:CAPR) by 571.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 179,301 shares of the biotechnology company’s stock after purchasing an additional 152,614 shares during the quarter. Virtu KCG Holdings LLC owned 0.79% of Capricor Therapeutics worth $149,000 as of its most recent filing with the Securities and Exchange Commission.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Capricor Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.